Abbott Laboratories vs Pfizer
ABT and PFE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABT and PFE compare
Abbott Laboratories and Pfizer are about the same size, with market caps of $188B and $164B.
On earnings, Abbott Laboratories is cheaper: it trades at 40.2× trailing earnings, against 41.2× for Pfizer.
Abbott Laboratories grew revenue faster over the last twelve months (10.0% versus 1.3% for Pfizer).
Abbott Laboratories keeps more of each dollar of sales as profit, with a net margin of 9.7% compared with 6.3% at Pfizer.
Both pay dividends: Abbott Laboratories yields 2.3% and Pfizer 4.5%.
Abbott Laboratories scores higher on the StockData Score (12 against 8 for Pfizer), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABT | PFE |
|---|---|---|
| Size and price | ||
| Market cap | $188B | $164B |
| Share price | $108.52 | $28.83 |
| Change, 1 year | −15.8% | 13.0% |
| Change, 5 years | −14.4% | −43.2% |
| Beta (5Y) | 0.45 | 0.44 |
| Employees | 115K | 75K |
| StockData Score | ||
| Total score | 12 (better) | 8 |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 0 |
| Performance score | 3 (better) | 2 |
| Health score | 4 (better) | 2 |
| Dividend score | 2 | 3 (better) |
| Valuation | ||
| P/E | 40.2× (better) | 41.2× |
| P/S | 3.9× | 2.6× (better) |
| P/B | 3.7× | 1.8× (better) |
| EV/EBITDA | 32.4× | 16.1× (better) |
| P/FCF | 27.8× | 13.9× (better) |
| FCF yield | 3.6% | 7.2% (better) |
| Fair value | $72.76 | $20.06 |
| Margin of safety | −49.1% | −43.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.0% (better) | 1.3% |
| Revenue growth, 5Y average | 5.1% | 8.5% (better) |
| Net income growth (TTM) | −66.4% | −59.0% (better) |
| EPS growth (TTM) | −66.2% | −59.3% (better) |
| EPS growth, 5Y average | 8.3% (better) | −3.6% |
| Profitability | ||
| Gross margin | 56.9% | 73.4% (better) |
| Operating margin | 13.8% | – |
| Net margin | 9.7% (better) | 6.3% |
| FCF margin | 14.0% | 18.5% (better) |
| Return on equity | 9.2% (better) | 4.4% |
| Return on invested capital | 7.1% | – |
| Financial health | ||
| Debt / equity | 0.61 (better) | 0.70 |
| Net debt / EBITDA | 4.04 | 3.84 (better) |
| Interest coverage | 6.7× | – |
| Current ratio | 1.45 (better) | 1.42 |
| Altman Z-score | 3.36 (better) | 2.03 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 2.3% | 4.5% (better) |
| Payout ratio | 92.0% | – |
| Years of dividend growth | 3 | 15 (better) |
| Dividend growth, 5Y average | – | 2.4% |
| Buyback yield | 0.82% | – |
| Shareholder yield | 3.1% | 4.5% (better) |
| Ownership | ||
| Held by institutions | 79.8% | 67.2% |
| Held by insiders | 0.50% | 0.03% |
| Insider net buying, 12 months | −$43.3M | $2.8M (better) |
| Superinvestors holding | 2 | 2 |
| Short interest, % of float | 1.1% | 2.4% |
Go deeper
- ABT stock overview
- ABT income statement
- ABT valuation and score
- PFE stock overview
- PFE income statement
- PFE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.